"name","label","id","instanceType","rationale","uuid:ID","description"
"Study Design 1","","StudyDesign_1","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","af7eaaf5-f507-439c-8259-f8d311d4fcc6","The main design for the study"
